ubmslateRN-logo-ubm

RN Mobile Menu

Search form

Topics:

Doctors Don’t Always Agree on Gout’s Origins and Treatment

Doctors Don’t Always Agree on Gout’s Origins and Treatment

  • (©Artemida-psy/Shutterstock.com)
    (©Artemida-psy/Shutterstock.com)
How do rheumatologists and primary care physicians differ in treating patients with gout? A survey funded by Ironwood Pharmaceuticals, the maker of Zurampic (lesinurad), shows that while they generally agree on most matters, there are differences in their definition of the disease and its treatment — which can be life-threatening for some patients.
 
The survey, which was conducted by Edelman Intelligence between Aug. 16 - 22, 2016, includes feedback from 250 primary care providers and 100 rheumatologists.
 
The survey shows that instead of managing the disease from a comprehensive standpoint, patients too often tend to seek care only during flares. And, as a result, half of patients are not meeting their serum uric acid (SUA) level targets (<6 mg/dl (360 μmol/l).
 
Poor education and misconceptions about disease management continue to contribute to ineffective disease management, said Paul Doghramji, M.D., a family physician from Collegeville, Penn., who is a consultant for Ironwood.
 
“What I find most concerning about these findings is that we as physicians agree gout is not only a painful, often debilitating disease, but can have long-term consequences like permanent joint damage. Moreover, studies are showing a good deal of association between gout and comorbid conditions such as cardiovascular disease and kidney disease. Yet clinicians who treat patients with gout are only getting about half of those patients to their target sUA levels,” Dr. Doghramji said.
 
This slideshow highlights the survey findings.
 
Disclosures: 

This survey was funded by Ironwood Pharmaceuticals.

Dr. Paul Doghramji, M.D., is a consultant for Ironwood.

The complete survey results are posted online at:  www.goutisserious.com

References: 
1. Physician Survey Executive Summary. Ironwood Pharmaceuticals. 2016.
2. Perez-Ruiz F, Herrero-Beites A. Evaluation and Treatment of Gout as a Chronic Disease. Adv Ther. 2012;29(11):935–946.
3. Schumacher HR. The pathogenesis of gout. Cleve Clin J Med. 2008;75(5):S2-S4.
4. Zhu Y, et al. Prevalence of Gout and Hyperuricemia in the US General Population. Arthritis Rheum. 2011;63:3136–41.
5. Richette P, Bardin T. Gout. Lancet. 2010;375(9711):318-328.
6. Khanna D, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64:1431-1446.
7. Scott J, Pollard A. Uric acid excretion in the relatives of patients with gout. Ann. Rheum. Dis. 1970;29(4):397-400.
8. Juraschek SP, et al. Gout, Urate Lowering Therapy and Uric Acid Levels among US Adults. Arthritis Care Res. 2015;67(4):558-592.
9. Wood R, et al. Patients with Gout Treated with Conventional Urate-lowering Therapy: Association with Disease Control, Health-related Quality of Life, and Work Productivity. J Rheumatol. 2016;1-7.
10. Khanna P, et al. A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift. Postgrad Med. 2016;128(1):34-40.
11. Meyer M, et al. Trends in Medication Utilization and the Cost of Treatment for Gout. Am J Pharmacy Ben. 2015;5(3):123-128.
12. Primatesta P, et al. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskeletal Dis. 2011;12:130:1-7.
13. Singh JA, Akhras KS and Shiozawa A. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Arthritis Res & Ther. 2015;17:120:1-12.
14. AZN/Decision Resource Market Research.
 

Comments

Mikhail

Mikhail @

Add new comment

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.